Navigation Links
Novel Xeloda(R) Dosing Schedule May Offer Well-Tolerated Alternative for Treatment of Advanced Breast Cancer
Date:4/18/2008

r parts of the body, has an especially poor prognosis, with a five-year survival rate of 27 percent. Currently, there are two and a half million breast cancer survivors in the United States. According to the ACS, breast cancer death rates are going down; the decline may be the result of early detection and treatment.

About the Study

Prior to study initiation, the Norton-Simon mathematical model (Norton et al, AACR 2005) -- which explores how the growth characteristics of a cancer affect response to chemotherapy -- was applied to determine that the maximum impact of Xeloda treatment in breast cancer patients occurs after seven days. Based on this finding, the single-center, open-label phase I/II trial was designed to determine the maximum tolerated dose (MTD) of Xeloda administered orally for seven days, followed by a seven-day rest (7-on/7-off), in patients with advanced-stage breast cancer. MTD was defined as the highest dose for which the incidence of dose-limiting toxicity (DLT) is less than 33 percent. DLT was defined as grade 3/4 hematologic toxicity lasting greater than two weeks despite growth factor support, or any grade 3/4 nonhematologic toxicity.

The Phase I study dose escalation scheme was a standard "3+3" design, using flat dosing that begins at 1,500 mg twice daily and increases by 500 mg/dose level until the MTD is reached. All patients in a cohort were observed for 28 days before enrollment to the next level is permitted to monitor for delayed toxicity.

The study showed that the dose dense regimen was well-tolerated in patients with advanced breast cancer, allowing safe delivery of higher daily doses than routinely used in practice. Of the 21 patients recruited for the trial, 18 were treated with Xeloda and reached a maximum tolerated dose of 2,000 mg twice daily. There were no grade 4/5 toxicities and grade 3 toxicities (which included one dose-limiting incident of hand-foot syndrome at 2,000 mg twice daily and two at 2,0
'/>"/>

SOURCE Roche
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Novel Technology Breaks Through Cancer Pain
2. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
3. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
4. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
5. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
6. The Lancet Publishes Major Phase 3 Study on Novel Oral Direct Thrombin Inhibitor
7. Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
8. Phase 2 Clinical Studies Initiated for a Novel Therapeutic Candidate Identified Through Pharmacopeia Collaboration
9. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
10. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
11. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... 2014  Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage ... pain, announced today that Sergio Traversa , chief ... MICRO "MAIN Event" Micro-Cap Growth Conference on Wednesday, December ... Luxe Sunset Bel Air Hotel, which is located at ... . The presentation is scheduled for ...
(Date:11/24/2014)... , Nov. 24, 2014  AiCure, an artificial ... technology to monitor medication ingestion, has announced the ... and intervene with patients receiving medication as maintenance ... overdoses from prescription opiates have quadrupled in the ... per year than heroin, cocaine and benzodiazepines combined. ...
(Date:11/24/2014)... 24, 2014  GlySens Incorporated announced today that it ... from the National Institute of Diabetes and Digestive and ... of Health (NIH).  The grant is intended to support ... long term implantable glucose monitoring system.  Final preparations for ... expected to begin before the end of 2014. ...
Breaking Medicine Technology:Relmada Therapeutics To Present At LD MICRO Conference 2Can artificial intelligence solve the $55 billion problem of opioid abuse? 2GlySens Incorporated Awarded $2 Million Grant from the National Institutes of Health 2
... --  Empire Genomics today announced that it has ... portfolio for the Japanese market.  The deal represents Empire,s international ... "We are excited to have such a proven and expert ... access to our broad genomic product and service portfolio," said ...
... MYL ) today announced that its subsidiary Mylan Pharmaceuticals Inc. ... Administration (FDA) for its Abbreviated New Drug Application (ANDA) for ... mg, 15 mg, and 20 mg. This product is the ... which is indicated for the treatment of schizophrenia and the ...
Cached Medicine Technology:Empire Genomics Chooses Funakoshi as Japan Distributor 2Mylan Launches Generic Version of Zyprexa® Tablets 2
(Date:11/23/2014)... 2014 Tbdress.com has recently announced ... on Nov. 28, 2014. The special offer will provide ladies ... is one of the world’s largest women’s dresses retailers, and ... People can enjoy great discounts on that day: Everything at ... delivery (for orders above $89). , People can use the ...
(Date:11/23/2014)... 2014 (HealthDay News) -- Close friends have more influence ... does, a new study says. "We,ve known ... an influence on individual alcohol use, but there are ... group and the friend group,s influence on those decisions," ... of Public Health, said in a university news release. ...
(Date:11/23/2014)... This evaluation provides a basic conclusion ... and manufacturing technological innovation. Then, the evaluation investigates ... in information. In this part, the evaluation provides ... and 2009-2014 market shares for each company. Through ... and Chinese suppliers finish market of Femoral Occurs ...
(Date:11/23/2014)... More than two dozen new claims were ... involving Byetta lawsuits ( http://www.byettalawsuit2013.com/ ), as well as ... , A Case List updated on November 17th ... 2 diabetes medications referred to as incretin mimetics have ... District of California, where a federal proceeding continues to ...
(Date:11/23/2014)... “BlackVue” was featured on NewsWatch as part of ... latest and coolest technology products available to consumers. Mallory ... the product review and shared with viewers how their ... car camera industry. , The need for in-car video ... find the one that’s right per consumer, especially considering ...
Breaking Medicine News(10 mins):Health News:Tbdress.com Special Friday Shoes Sales Online Now 2Health News:Close Friends May Be Key to Teens' Drinking 2Health News:Femoral Stems Industry 2014 Analysis & 2019 Forecasts for Global and Chinese Region in New Research Report at ReportsnReports.com 2Health News:Femoral Stems Industry 2014 Analysis & 2019 Forecasts for Global and Chinese Region in New Research Report at ReportsnReports.com 3Health News:Femoral Stems Industry 2014 Analysis & 2019 Forecasts for Global and Chinese Region in New Research Report at ReportsnReports.com 4Health News:California Federal Court Overseeing Byetta Lawsuits, Other Incretin Mimetic Claims Adds New Cases in November, Bernstein Liebhard LLP Reports 2Health News:California Federal Court Overseeing Byetta Lawsuits, Other Incretin Mimetic Claims Adds New Cases in November, Bernstein Liebhard LLP Reports 3Health News:California Federal Court Overseeing Byetta Lawsuits, Other Incretin Mimetic Claims Adds New Cases in November, Bernstein Liebhard LLP Reports 4Health News:A Leader in Front and Rear Facing In-Car Cameras was Featured on NewsWatch Television on October 30, 2014 2
... Patients with obstructive sleep apnea (OSA) who ... of continuous positive airway pressure (CPAP) relieves them of ... the October 15 issue of the Journal of Clinical ... The Sleep Center at Universitys Community Hospital in Tampa, ...
... published in the October 15 issue of the Journal ... Sleepiness Questionnaire (CASQ), a new self-completed instrument to measure ... by James C. Spilsbury, PhD, of the Division of ... a subsample of 411 adolescents between 11-17 years of ...
... France, October 15 Sanofi Pasteur, the,vaccines ... partnership,with Institut Pasteur to develop a vaccine ... will have access to antigens,identified by Institut ... for the most deadly malaria infections. Sanofi ...
... SEATTLE, October 15 - ,Real Women, Real ... Recognition and Treatment in Women Around the World ... (IASP) has,declared 2008 the Global Year Against Pain in ... pain on women and the need for more,effective care. ...
... leading cancer organizations shows cancer death rates decreased on ... nearly twice the annual decrease of 1.1 percent per ... in the Annual Report to the Nation on the ... and Alaska Natives published online October 15, 2007 ( ...
... One of the most distressing aspects of Alzheimer,s disease is ... beginning of an inevitable mental decline. Researchers at the Stanford ... is a step toward giving people an answer two to ... , The test identifies changes in a handful of proteins ...
Cached Medicine News:Health News:New tool to assess excessive daytime sleepiness in adolescents published in JCSM 2Health News:Sanofi Pasteur and Institut Pasteur Team up Against Malaria 2Health News:Sanofi Pasteur and Institut Pasteur Team up Against Malaria 3Health News:International Association for the Study of Pain (IASP) Declares the Global Year Against Pain in Women 2Health News:International Association for the Study of Pain (IASP) Declares the Global Year Against Pain in Women 3Health News:Annual report to the nation finds cancer death rate decline doubling 2Health News:Annual report to the nation finds cancer death rate decline doubling 3Health News:Annual report to the nation finds cancer death rate decline doubling 4Health News:Blood test takes step toward predicting Alzheimer's risk, Stanford researchers find 2Health News:Blood test takes step toward predicting Alzheimer's risk, Stanford researchers find 3Health News:Blood test takes step toward predicting Alzheimer's risk, Stanford researchers find 4
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: